| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; Chia-Chi Lin; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J. |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali P.A.; Chia-Chi Lin; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; Shen Y.-C.; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J. |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; Chia-Chi Lin; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J. |
| 臺大學術典藏 |
2022-09-15T01:08:44Z |
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
|
Italiano A.; Cassier P.A.; Chia-Chi Lin; Alanko T.; Peltola K.J.; Gazzah A.; Shiah H.-S.; Calvo E.; Cervantes A.; Roda D.; Tosi D.; Gao B.; Millward M.; Warburton L.; Tanner M.; Englert S.; Lambert S.; Parikh A.; Afar D.E.; Vosganian G.; Moreno V. |
| 臺大學術典藏 |
2022-03-15T05:39:21Z |
B cells are associated with survival and immunotherapy response in sarcoma
|
Petitprez F.; de Reyni?s A.; Keung E.Z.; WEI-WU CHEN; Sun C.-M.; Calderaro J.; Jeng Y.-M.; Hsiao L.-P.; Lacroix L.; Bougo?in A.; Moreira M.; Lacroix G.; Natario I.; Adam J.; Lucchesi C.; Laizet Y.; Toulmonde M.; Burgess M.A.; Bolejack V.; Reinke D.; Wani K.M.; Wang W.-L.; Lazar A.J.; Roland C.L.; Wargo J.A.; Italiano A.; Saut?s-Fridman C.; Tawbi H.A.; Fridman W.H. |
| 臺大學術典藏 |
2022-03-15T05:39:20Z |
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
|
Gounder M.; Sch?ffski P.; Jones R.L.; Agulnik M.; Cote G.M.; Villalobos V.M.; Attia S.; Chugh R.; WEI-WU CHEN; Jahan T.; Loggers E.T.; Gupta A.; Italiano A.; Demetri G.D.; Ratan R.; Davis L.E.; Mir O.; Dileo P.; Van Tine B.A.; Pressey J.G.; Lingaraj T.; Rajarethinam A.; Sierra L.; Agarwal S.; Stacchiotti S. |
| 臺大學術典藏 |
2022-03-15T05:39:18Z |
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature
|
Frezza A.M.; Ravi V.; Lo Vullo S.; Vincenzi B.; Tolomeo F.; WEI-WU CHEN; Teterycz P.; Baldi G.G.; Italiano A.; Penel N.; Brunello A.; Duffaud F.; Hindi N.; Iwata S.; Smrke A.; Fedenko A.; Gelderblom H.; Van Der Graaf W.; Vozy A.; Connolly E.; Grassi M.; Benjamin R.S.; Broto J.-M.; Grignani G.; Jones R.L.; Kawai A.; Tysarowski A.; Mariani L.; Casali P.G.; Stacchiotti S. |
| 臺大學術典藏 |
2022-02-21T02:51:54Z |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali P.A.; Lin C.-C.; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; YING-CHUN SHEN; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J. |
| 國立成功大學 |
2022 |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali, P.A.;Lin, C.-C.;Carthon, B.C.;Bauer, T.M.;Tucci, M.;Italiano, A.;Iacovelli, R.;Su, W.-C.;Massard, C.;Saleh, M.;Daniele, G.;Greystoke, A.;Gutierrez, M.;Pant, S.;Shen, Y.-C.;Perrino, M.;Meng, R.;Abbadessa, G.;Lee, H.;Dong, Y.;Chiron, M.;Wang, R.;Loumagne, Loumagne L.;L�pine, L�pine L.;De, Bono J. |
| 臺大學術典藏 |
2021-04-29T00:48:10Z |
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature
|
Frezza A.M.; Ravi V.; Lo Vullo S.; Vincenzi B.; Tolomeo F.; WEI-WU CHEN; Teterycz P.; Baldi G.G.; Italiano A.; Penel N.; Brunello A.; Duffaud F.; Hindi N.; Iwata S.; Smrke A.; Fedenko A.; Gelderblom H.; Van Der Graaf W.; Vozy A.; Connolly E.; Grassi M.; Benjamin R.S.; Broto J.-M.; Grignani G.; Jones R.L.; Kawai A.; Tysarowski A.; Mariani L.; Casali P.G.; Stacchiotti S. |
| 臺大學術典藏 |
2021-03-18T03:23:31Z |
B cells are associated with survival and immunotherapy response in sarcoma
|
Petitprez F.; de Reyni?s A.; Keung E.Z.; WEI-WU CHEN; Sun C.-M.; Calderaro J.; Jeng Y.-M.; Hsiao L.-P.; Lacroix L.; Bougo?in A.; Moreira M.; Lacroix G.; Natario I.; Adam J.; Lucchesi C.; Laizet Y.; Toulmonde M.; Burgess M.A.; Bolejack V.; Reinke D.; Wani K.M.; Wang W.-L.; Lazar A.J.; Roland C.L.; Wargo J.A.; Italiano A.; Saut?s-Fridman C.; Tawbi H.A.; Fridman W.H. |
| 臺大學術典藏 |
2021-03-18T03:23:29Z |
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
|
Gounder M.; Sch?ffski P.; Jones R.L.; Agulnik M.; Cote G.M.; Villalobos V.M.; Attia S.; Chugh R.; WEI-WU CHEN; Jahan T.; Loggers E.T.; Gupta A.; Italiano A.; Demetri G.D.; Ratan R.; Davis L.E.; Mir O.; Dileo P.; Van Tine B.A.; Pressey J.G.; Lingaraj T.; Rajarethinam A.; Sierra L.; Agarwal S.; Stacchiotti S. |
| 國立成功大學 |
2021 |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque, A.;Chung, H.C.;Miguel, Miguel M.J.D.;Italiano, A.;MacHiels, J.-P.;Lin, C.-C.;Dhani, N.C.;Peeters, M.;Moreno, V.;Su, W.-C.;Chow, K.H.;Galvao, V.R.;Carlse, M.;Yu, D.;Szpurka, A.M.;Zhao, Y.;Schmidt, Schmidt S.L.;Gandhi, L.;Xu, Xu X.;Bang, Y.-J. |
| 國立成功大學 |
2021 |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik, A.;Yap, T.A.;Chung, H.C.;de, Miguel M.J.;Bang, Y.-J.;Lin, C.-C.;Su, W.-C.;Italiano, A.;Chow, K.H.;Szpurka, A.M.;Yu, D.;Zhao, Y.;Carlsen, M.;Schmidt, Schmidt S.;Vangerow, B.;Gandhi, L.;Xu, Xu X.;Bendell, J. |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|
Havel L; Pauk N; Singh J; Murakami S; Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Juat N;Hagenstad C;Einspahr D;Crin? L;Bocskei C;Page R;Levy B;Koubkova L;Khanani S;Juhasz E;Torri V;Iqbal M;Anderson I;Price A;Losonczy G;Csoszi T;Murakami S;Singh J;Pauk N;Havel L;Coupkova H;Cernovska M;Sebastian M;Schulte C;Ladrera G.E.I;Kobayashi K;Daniel D;Panwalkar A;Mohn-Staudner A;Juan Vidal O;Takeda K;Kato T;Gettinger S;Hirashima T;Tan E.H;Sugawara S;Nakagawa K;Querol J;Reynolds J;Haigentz M;Iannotti N;Boccia R;Ikeda N;Hesketh P;Giridharan S;Chaudhry A;Herzmann C;Chang G.-C;Satouchi M;Mark Z;Coudert B;Waterhouse D;Waller C;Kubota K;Vrindavanam N;Malcolm A;Palmero Sanchez R;Juergens R;Jassem J;Chachoua A;Feld R;Bradbury P;Azuma K;Kemmotsu H;Aglietta M;Scholz C;Canon J.-L;Weiss G;Bosch-Barrera J;Goto K;Vincent M;Sakai H;Denis F;Hsia T.-C;Chih-Hsin Yang;Alvarez Alvarez R;Garcia Gomez R;Chewaskulyong B;Spigel D;Chen Y.-M;Barlesi F;Kowalski D;Italiano A;Lucien Geater S;Uy M.N;Santoro A;Kubiak K;Zylla D;Maeda T;Derijcke S;Veillon R;Gabrail N;Imamura F;Nishio M;Spaeth-Schwalbe E;Atagi S;Kang E.J;Yokoi T;Sibille A;Ramos Garcia I;Milella M;Saka H;Lee J.-S;Wolf J;Kim Y.-C;Su W.-C;Katakami N;Atlantic Investigators;Szalai Z;Garrison M;Overton L;Cheema P;Thomas M;Soto Parra H;Robinet G;Chopra A;Chella A;Oe Y;Belda Iniesta C;Holgado Martin E;Han J.-Y;Reck M;Surmont V;Kim D.-W;Berghmans T;Vicente Baz D;Chaft J;Kim S.-W;Maemondo M;Califano R;Laack E;Schmid P;Hiret S;Novello S;Paz-Ares Rodriguez L;Rizvi N.A;Dennis P.A;Wadsworth C;Huang Y;Soo R.A;Park K;Wheatley-Price P;Bidoli P;Chouaid C;Powderly J;Gray J.E;Corral Jaime J;Lena H;Vansteenkiste J;Mazi?res J;Kim J.-H;Cho B.-C;Garassino M.C |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|
Havel L; Pauk N; Singh J; Murakami S; Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Juat N;Hagenstad C;Einspahr D;Crin? L;Bocskei C;Page R;Levy B;Koubkova L;Khanani S;Juhasz E;Torri V;Iqbal M;Anderson I;Price A;Losonczy G;Csoszi T;Murakami S;Singh J;Pauk N;Havel L;Coupkova H;Cernovska M;Sebastian M;Schulte C;Ladrera G.E.I;Kobayashi K;Daniel D;Panwalkar A;Mohn-Staudner A;Juan Vidal O;Takeda K;Kato T;Gettinger S;Hirashima T;Tan E.H;Sugawara S;Nakagawa K;Querol J;Reynolds J;Haigentz M;Iannotti N;Boccia R;Ikeda N;Hesketh P;Giridharan S;Chaudhry A;Herzmann C;Chang G.-C;Satouchi M;Mark Z;Coudert B;Waterhouse D;Waller C;Kubota K;Vrindavanam N;Malcolm A;Palmero Sanchez R;Juergens R;Jassem J;Chachoua A;Feld R;Bradbury P;Azuma K;Kemmotsu H;Aglietta M;Scholz C;Canon J.-L;Weiss G;Bosch-Barrera J;Goto K;Vincent M;Sakai H;Denis F;Hsia T.-C;Chih-Hsin Yang;Alvarez Alvarez R;Garcia Gomez R;Chewaskulyong B;Spigel D;Chen Y.-M;Barlesi F;Kowalski D;Italiano A;Lucien Geater S;Uy M.N;Santoro A;Kubiak K;Zylla D;Maeda T;Derijcke S;Veillon R;Gabrail N;Imamura F;Nishio M;Spaeth-Schwalbe E;Atagi S;Kang E.J;Yokoi T;Sibille A;Ramos Garcia I;Milella M;Saka H;Lee J.-S;Wolf J;Kim Y.-C;Su W.-C;Katakami N;Atlantic Investigators;Szalai Z;Garrison M;Overton L;Cheema P;Thomas M;Soto Parra H;Robinet G;Chopra A;Chella A;Oe Y;Belda Iniesta C;Holgado Martin E;Han J.-Y;Reck M;Surmont V;Kim D.-W;Berghmans T;Vicente Baz D;Chaft J;Kim S.-W;Maemondo M;Califano R;Laack E;Schmid P;Hiret S;Novello S;Paz-Ares Rodriguez L;Rizvi N.A;Dennis P.A;Wadsworth C;Huang Y;Soo R.A;Park K;Wheatley-Price P;Bidoli P;Chouaid C;Powderly J;Gray J.E;Corral Jaime J;Lena H;Vansteenkiste J;Mazi?res J;Kim J.-H;Cho B.-C;Garassino M.C |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891
|
Powderly J; Cassier P.A; Cervantes A; Gao B; Gazzah A; Italiano A; Chia-Chi Lin; Luke J.J; Moreno V; Peltola K; Rasco D; Spira A.I; Tanner M.M.E; Tosi D; Afar D; Englert S; Parikh A; Reddy A; Vosganian G; Tolcher A.W. |
| 臺大學術典藏 |
2020-03-06T08:24:45Z |
B cells are associated with survival and immunotherapy response in sarcoma
|
Lazar A.J.; Roland C.L.; Wargo J.A.; Italiano A.; Sautès-Fridman C.; Tawbi H.A.; Fridman W.H.; Petitprez F.;De Reyni?s A.;Keung E.Z.;Chen T.W.-W.;Sun C.-M.;Calderaro J.;Yung-Ming Jeng;Hsiao L.-P.;Lacroix L.;Bougo?in A.;Moreira M.;Lacroix G.;Natario I.;Adam J.;Lucchesi C.;Laizet Y.;Toulmonde M.;Burgess M.A.;Bolejack V.;Reinke D.;Wani K.M.;Wang W.-L.;Lazar A.J.;Roland C.L.;Wargo J.A.;Italiano A.;Saut?s-Fridman C.;Tawbi H.A.;Fridman W.H.; Petitprez F.; de Reyniès A.; Keung E.Z.; Chen T.W.-W.; Sun C.-M.; Calderaro J.; YUNG-MING JENG; Hsiao L.-P.; Lacroix L.; Bougoüin A.; Moreira M.; Lacroix G.; Natario I.; Adam J.; Lucchesi C.; Laizet Y.; Toulmonde M.; Burgess M.A.; Bolejack V.; Reinke D.; Wani K.M.; Wang W.-L. |
| 臺大學術典藏 |
2020-03-06T08:24:45Z |
B cells are associated with survival and immunotherapy response in sarcoma
|
Lazar A.J.; Roland C.L.; Wargo J.A.; Italiano A.; Sautès-Fridman C.; Tawbi H.A.; Fridman W.H.; Petitprez F.;De Reyni?s A.;Keung E.Z.;Chen T.W.-W.;Sun C.-M.;Calderaro J.;Yung-Ming Jeng;Hsiao L.-P.;Lacroix L.;Bougo?in A.;Moreira M.;Lacroix G.;Natario I.;Adam J.;Lucchesi C.;Laizet Y.;Toulmonde M.;Burgess M.A.;Bolejack V.;Reinke D.;Wani K.M.;Wang W.-L.;Lazar A.J.;Roland C.L.;Wargo J.A.;Italiano A.;Saut?s-Fridman C.;Tawbi H.A.;Fridman W.H.; Petitprez F.; de Reyniès A.; Keung E.Z.; Chen T.W.-W.; Sun C.-M.; Calderaro J.; YUNG-MING JENG; Hsiao L.-P.; Lacroix L.; Bougoüin A.; Moreira M.; Lacroix G.; Natario I.; Adam J.; Lucchesi C.; Laizet Y.; Toulmonde M.; Burgess M.A.; Bolejack V.; Reinke D.; Wani K.M.; Wang W.-L. |
